Holen Sie sich die Stockscreener-App
0.691
4.33%
-0.0313
Handel nachbörslich:
.69
-0.001
-0.14%
Schlusskurs vom Vortag:
$0.7223
Offen:
$0.73
24-Stunden-Volumen:
62,481
Relative Volume:
0.76
Marktkapitalisierung:
$29.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-74.56M
KGV:
-0.3773
EPS:
-1.8316
Netto-Cashflow:
$-60.27M
1W Leistung:
-7.51%
1M Leistung:
-20.44%
6M Leistung:
-37.18%
1J Leistung:
-70.72%
1-Tages-Spanne:
$0.68
$0.73
1-Wochen-Bereich:
$0.68
$0.7731
52-Wochen-Spanne:
$0.68
$3.46
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Vergleichen Sie RLYB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.691 | 29.04M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-10 | Eingeleitet | Wedbush | Outperform |
| 2022-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-08-23 | Eingeleitet | Cowen | Outperform |
| 2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Rallybio stock hits 52-week low at $0.68 amid market challenges - Investing.com UK
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
New Haven-based biotech Rallybio faces delisting from Nasdaq - Hartford Business Journal
Rallybio faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
Rallybio faces Nasdaq delisting over share price woes - Investing.com India
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
Rallybio stock plunges to 52-week low at $0.72 amid market challenges - Investing.com
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe - MSN
Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World
Rallybio stock plunges to 52-week low of $0.73 amid market challenges - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy By Investing.com - Investing.com Nigeria
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire
Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Jane Street Group LLC Has $26,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World
Geode Capital Management LLC Has $287,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - BioSpace
Rallybio Advances Rare Disease Pipeline: Phase 2 FNAIT Trial Launch, Key Programs Progress - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Rallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com
Rallybio stock plunges to 52-week low, touches $0.94 By Investing.com - Investing.com South Africa
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK
Fmr LLC Acquires 25,422 Shares of Rallybio Co. (NASDAQ:RLYB) - Defense World
US Penny Stocks To Consider In December 2024 - Simply Wall St
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire
Rallybio price target lowered to $7 from $8 at JMP Securities - Yahoo Finance
Rallybio shares retains Buy rating on treatment potential By Investing.com - Investing.com Australia
Rallybio shares retains Buy rating on treatment potential - Investing.com
Rallybio : RLYB116 Clinical Program Update – Harnessing the Power of C5 Inhibition - Marketscreener.com
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
Rallybio advances Phase 2 trial for rare pregnancy condition By Investing.com - Investing.com Nigeria
Rallybio Flat On Release Of New Findings - MENAFN.COM
Rallybio Flat on Release of New Findings - Baystreet.ca
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):